138227-68-6

Basic information

• Product Name: 1N-BOC 4-(2'-METHYL-4'-NITROPHENOXY) PIPERIDINE
• Synonyms: 1N-BOC 4-(2'-METHYL-4'-NITROPHENOXY) PIPERIDINE;1-Boc-4-(2'-methyl-4'-nitrophenoxy)piperidine;tert-Butyl 4-(2-Methyl-4-nitrophenoxy)piperidine-1-carboxylate
• CAS NO: 138227-68-6
• Molecular Formula: C₁₇H₂₄N₂O₅
• Molecular Weight: 336.38
• Mol File: 138227-68-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1N-BOC 4-(2'-METHYL-4'-NITROPHENOXY) PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1N-BOC 4-(2'-METHYL-4'-NITROPHENOXY) PIPERIDINE(138227-68-6)
• EPA Substance Registry System: 1N-BOC 4-(2'-METHYL-4'-NITROPHENOXY) PIPERIDINE(138227-68-6)

Safety Data

• Hazardous Substances Data: 138227-68-6(Hazardous Substances Data)

Usage

Class

Piperidines

Structure

Six-membered heterocyclic ring containing five carbon atoms and one nitrogen atom

Derivative

BOC (tert-butoxycarbonyl) protecting group

Substituent

2'-methyl and 4'-nitrophenoxy

Usage

Organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and bioactive compounds

Reactivity

Unique structure and reactivity make it a valuable intermediate in the synthesis of diverse drug candidates and molecular probes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 99-53-6 2-methyl-4-nitrophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1972-28-7 diethylazodicarboxylate 
• 455-88-9 5-nitro-2-fluorotoluene 

Downstream Products

• 405887-72-1 C₂₁H₃₄N₂O₅Si 
• 405887-73-2 C₂₁H₃₄N₂O₅Si 
• 138227-69-7 1-tert-butyloxycarbonyl-4-(4-amino-2-methylphenyloxy)piperidine 
• 807319-25-1 C₂₆H₃₄N₄O₅ 
• 807319-24-0 C₂₂H₂₆N₄O₃ 

Relevant articles and documents

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).

The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer

The synthesis and biological evaluation of potent and selective inhibitors of the erbB2 kinase is presented. Based on the 4-anilinoquinazoline chemotype, the syntheses of several new series of erbB2 inhibitors are described with quinazoline and pyrido[4,3

SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

-